Dj Lisata Therapeutics Inc Com, Inst Holders, 3Q 2025 (Lsta)

Reuters

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research GmbH): BUY

EQS

Lisata Therapeutics

-1.02%

Original-Research: Lisata Therapeutics Inc - from First Berlin Equity Research GmbH

17.11.2025 / 15:19 CET/CEST

Dissemination of a Research, transmitted by EQS News - a service of EQS Group.

The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.

Classification of First Berlin Equity Research GmbH to Lisata Therapeutics Inc

Company Name:	Lisata Therapeutics Inc
ISIN:

Reason for the research:	Update
Recommendation:	BUY
from:	17.11.2025
Target price:	USD 15
Target price on sight of:	12 months
Last rating change:	-
Analyst:	Christian Orquera

First Berlin Equity Research has published a research update on Lisata Therapeutics, Inc. (ISIN: ). Analyst Christian Orquera reiterated his BUY rating and maintained his USD 15.00 price target. Abstract: Lisata reported 9M/25 results slightly ahead of our expectations, chiefly driven by continued operational discipline and reduced external R&D spending. OPEX fell 13% YoY to USD 15.2m (FBe: USD 17.0m; 9M/24: USD 17.5m), reflecting lower manufacturing and CRO costs as earlier-stage studies concluded and partner-supported trials absorbed more of the R&D burden. Cash and marketable securities came in at USD 19.0m (FBe: USD 18.5m; FY/24: USD 31.2m), providing a cash runway into Q1/27 (previously: Q4/26). Operationally, Q3 was marked by further progress across Lisata's certepetide platform. Encouraging data from the phase 1/2a CENDIFOX trial (n=50) presented at the AACR Conference on Pancreatic Cancer in Boston provided meaningful clinical and biological signals, supporting certepetide's potential to enhance chemotherapy effectiveness and reshape the tumour microenvironment in pancreatic ductal adenocarcinoma (PDAC), one of the deadliest and most treatment-resistant malignancies. Importantly, these findings complement and extend the positive data presented earlier in 2025 from the ASCEND and iLSTA studies, together forming a consistent body of evidence that supports certepetide's potential as a backbone therapy in multiple stages of PDAC. Lisata also broadened its platform reach through two strategic preclinical collaborations: (1) a global licence with Catalent, validating certepetide as a non-cytotoxic ADC payload in a market projected to exceed USD 25bn by 2030, and (2) an AI-driven alliance with GATC Health to apply multiomics analysis for pipeline optimisation and new indication discovery. These achievements confirm our positive view on Lisata and certepetide. We expect further upcoming milestones to support a re-rating of the stock. Based on unchanged estimates we reiterate our USD 15 price target and Buy rating (upside: >600%). First Berlin Equity Research hat ein Research Update zu Lisata Therapeutics, Inc. (ISIN: ) veröffentlicht. Analyst Christian Orquera bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von USD 15,00. Zusammenfassung: Lisata veröffentlichte Ergebnisse für die ersten neun Monate 2025, die leicht über unseren Erwartungen lagen, was in erster Linie auf die anhaltende operative Disziplin und geringere externe F&E-Ausgaben zurückzuführen ist. Die Betriebskosten sanken im Jahresvergleich um 13 % auf USD 15,2 Mio. (FBe: USD 17,0 Mio.; 9M/24: USD 17,5 Mio.), was auf niedrigere Fertigungs- und CRO-Kosten zurückzuführen ist, da Studien in früheren Phasen abgeschlossen wurden und von Partnern unterstützte Studien einen größeren Teil der F&E-Last übernommen haben. Die liquiden Mittel und marktfähigen Wertpapiere beliefen sich auf USD 19,0 Mio. (FBe: USD 18,5 Mio.; GJ/24: USD 31,2 Mio.), was eine Liquiditätsreichweite bis zum 1. Quartal 2027 (zuvor: 4. Quartal 2026) ermöglicht. Operativ war das 3. Quartal durch weitere Fortschritte bei der Certepetide-Plattform von Lisata gekennzeichnet. Die vielversprechenden Daten aus der Phase-1/2a-Studie CENDIFOX (n=50), die auf der AACR-Konferenz zu Bauchspeicheldrüsenkrebs in Boston vorgestellt wurden, lieferten aussagekräftige klinische und biologische Signale, die das Potenzial von Certepetide zur Steigerung der Wirksamkeit der Chemotherapie und zur Umgestaltung der Tumormikroumgebung bei duktalem Adenokarzinom des Pankreas (PDAC), einer der tödlichsten und behandlungsresistentesten Krebsarten, untermauern. Wichtig ist, dass diese Ergebnisse die bereits 2025 vorgestellten positiven Daten aus den Studien ASCEND und iLSTA ergänzen und erweitern und zusammen einen konsistenten Evidenzbestand bilden, der das Potenzial von Certepetide als Basistherapie in mehreren Stadien des PDAC untermauert. Lisata erweiterte außerdem die Reichweite seiner Plattform durch zwei strategische präklinische Kooperationen: (1) eine globale Lizenzvereinbarung mit Catalent, die Certepetide als nicht-zytotoxische ADC-Nutzlast in einem Markt validiert, dessen Wert bis 2030 voraussichtlich USD 25 Mrd. übersteigen wird, und (2) eine KI-gestützte Allianz mit GATC Health zur Anwendung von Multiomik-Analysen für die Pipeline-Optimierung und die Erforschung neuer Indikationen. Diese Erfolge bestätigen unsere positive Einschätzung von Lisata und Certepetide. Wir erwarten weitere Meilensteine, die eine Neubewertung der Aktie unterstützen werden. Auf der Grundlage unveränderter Schätzungen bekräftigen wir unser Kursziel von USD 15 und unsere Kaufempfehlung (Aufwärtspotenzial: >600%). Bezüglich der Pflichtangaben gem. §85 Abs. 1 S. 1 WpHG und des Haftungsausschlusses siehe die vollständige Analyse. You can download the research here: LSTA_US-2025-11-17_EN Contact for questions: First Berlin Equity Research GmbHHerr Gaurav TiwariTel.: +49 (0)30 809 39 686web: www.firstberlin.comE-Mail: g.tiwari@firstberlin.com

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

View original content: EQS News

2231152 17.11.2025 CET/CEST

Disclaimer

Saving the news in databases or any forwarding of the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.

Risk Warnings and Disclaimers

Add to Favorites

LSTA: Certepetide clinical progress, reduced expenses, and new partnerships drive a strong Q3 2025

Quartr

Lisata Therapeutics

-1.02%

Q3 2025 saw reduced expenses and net loss, with $19M in cash projected to last into Q1 2027. Certepetide advanced across multiple cancer trials, showing positive efficacy and safety signals, while new partnerships and a key patent strengthened the pipeline.

Based on Lisata Therapeutics, Inc. [LSTA] Q3 2025 Audio Transcript — Nov. 6 2025

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Risk Warnings and Disclaimers

Add to Favorites

Q3 2025 Lisata Therapeutics Inc Earnings Call

Reuters

Lisata Therapeutics

-1.02%

Risk Warnings and Disclaimers

Add to Favorites

Dj Lisata Therapeutics 3Q Rev $0.00 >Lsta

Reuters

Lisata Therapeutics

-1.02%

Risk Warnings and Disclaimers

Add to Favorites

Dj Lisata Therapeutics 3Q Loss/Shr 49C >Lsta

Reuters

Lisata Therapeutics

-1.02%

Risk Warnings and Disclaimers

Add to Favorites

Lisata Therapeutics Q3 Net Loss Narrows To $4.2 Million

Reuters

Lisata Therapeutics

-1.02%

Risk Warnings and Disclaimers

Add to Favorites

Risk Disclosure

The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

Recent Searches

Top Searches

Markets

News

Analysis

User

24/7

Economic Calendar

Education

Data

Dj Lisata Therapeutics Inc Com, Inst Holders, 3Q 2025 (Lsta)

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research GmbH): BUY

LSTA: Certepetide clinical progress, reduced expenses, and new partnerships drive a strong Q3 2025

Q3 2025 Lisata Therapeutics Inc Earnings Call

Dj Lisata Therapeutics 3Q Rev $0.00 >Lsta

Dj Lisata Therapeutics 3Q Loss/Shr 49C >Lsta

Lisata Therapeutics Q3 Net Loss Narrows To $4.2 Million

Risk Disclosure